Physician profile
Ninad Dixit
NPI 1922094655
$4,262.30
in general payments reported to CMS, 2019-2025
31 companies · $2,354 in 2025
The $2,354 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $86.01 · 2021: $61.12 · 2022: $51.84 · 2023: $69.14 · 2024: $1,519 · 2025: $2,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,941.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $589.02 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $493.13 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $464.09 | 2020-2025 | |
| Pfizer INC. | $368.06 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $277.57 | 2024-2025 | |
| Dexcom, INC. | $268.03 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $256.09 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Aimmune Therapeutics, INC. | $250.61 | 2024-2025 | Zenpep |
| Astellas Pharma US INC | $202.99 | 2024-2025 | Veozah |
| Boston Scientific Corporation | $149.97 | 2025 | Watchman Access System |
| Exact Sciences Corporation | $147.17 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.43 | 2019-2025 | Jardiance |
| Abbott Laboratories | $102.58 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $85.14 | 2024-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $74.68 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $60.74 | 2024 | Euflexxa |
| E.R. Squibb & Sons, L.L.C. | $37.72 | 2025 | Eliquis |
| Lundbeck LLC | $33.02 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $31.37 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $30.16 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Glaxosmithkline, LLC. | $28.14 | 2019-2021 | |
| Dynavax Technologies Corporation | $26.86 | 2024 | Heplisav-B |
| Genzyme Corporation | $24.15 | 2025 | |
| Recor Medical INC | $23.68 | 2025 | Paradise Ultrasound Renal Denervation System |
| Amarin Pharma, INC. | $23.61 | 2020 | |
| Philips North America LLC | $20.35 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.15 | 2024 | Xarelto |
| Emd Serono, INC. | $17.84 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.26 | 2019 | |
| Daiichi Sankyo INC. | $15.53 | 2024 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $13.16 | 2024 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ninad Dixit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.